US OptionsDetailed Quotes

INDV250516P7500

Watchlist

0.08
0.000.00%

15min DelayClose May 8 16:00 ET

0.00High0.00Low

Indivior Stock Discussion

Teddy123

May 1 23:12

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

$Indivior (INDV.US)$
Groundbreaking Study: New Treatment Option for Pregnant Women Battling Opioid Addiction Shows Promise

Teddy123

Feb 24 15:11

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

$Indivior (INDV.US)$
Game-Changing OUD Treatment Update: SUBLOCADE Now Offers 1-Hour Start Protocol

Teddy123

Feb 12 18:41

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

$Indivior (INDV.US)$
Unexpected FDA Delay: Indivior's SUBLOCADE Label Changes Face Setback Despite Clean Review

Jaguar8

Oct 10, 2024 19:07

NEWS

$Indivior (INDV.US)$
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance.
• Group now sees lower than expected Q3 2024 and FY 2024 SUBLOCADE net revenue (NR) from a combination of faster initial adoption among treatment providers of the...

Moomoo AI

Feb 22, 2024 22:25

Indivior's potential U.S. market move reflects its growth opportunities and is expected to attract more U.S. investors. Strong financial performance and positive revenue outlook may also boost investor interest.

Indivior Shares Jump on Possible U.S. Listing, Swing to Pretax Profit

No comment yet